Nabla Bio
PrivateLast Round
Series A
May 14, 2024
Total Funding Raised
$37.38M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Nabla Bio operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series A round in May 2024.
Nabla Bio is a biotechnology company that develops an AI-driven platform for the rational design of developable, selective, and functional antibody therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Foundation
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nabla Bio Comparables
Compare Nabla Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BigHat Biosciences | 89% | |
| Evozyne | 85% | |
| Chan Zuckerberg Biohub | 85% |
For institutional investors. Book with your work email.
Nabla Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 14, 2024 | ||||
| Seed | Dec 6, 2021 | ||||
| Grant | Apr 1, 2021 | ||||
| Accelerator | Aug 24, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Nabla Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Khosla Ventures | Series A, Seed |
| Cantos Ventures | Seed |
| Zetta Venture Partners | Series A, Seed |
| Pillar VC | Series A, Seed |
| Y Combinator | Accelerator |
| GRIDS Capital | Series A |
| Radical Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 22, 2026
Grew 17% QoQ, from 23 to 27 employees.
- Jan 1, 2026
Received coverage in Science Magazine and Endpoints News.
For institutional investors. Book with your work email.
Nabla Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nabla Bio's valuation, stock price, and market status.
Is Nabla Bio a public or private company?
Nabla Bio is a private company.
What is the current stock price of Nabla Bio?
Nabla Bio is a private company, so its shares have no public market price. Caplight tracks Nabla Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nabla Bio worth (valuation)?
Valuation information for Nabla Bio is not publicly available.
Can I buy Nabla Bio stock?
Nabla Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nabla Bio's last funding round?
Nabla Bio's most recent funding round was Series A on May 14, 2024.
Who are the main investors in Nabla Bio?
Key investors in Nabla Bio include Khosla Ventures, Zetta Venture Partners, Y Combinator, Radical Ventures.
Will Nabla Bio IPO soon?
No public IPO plans have been announced for Nabla Bio.
How can I track Nabla Bio secondary market activity?
Caplight tracks bids, offers, and trades in Nabla Bio's shares on secondary markets.